CL2017000232A1 - Cepas de salmonella gallinarum modificadas avirulentas; composición farmacéutica que la usan; aditivo para piensos; procedimiento de tratamiento de la tifosis aviar infecciosa por salmonellla gallinarum. (divisional solicitud 3285-2013) - Google Patents

Cepas de salmonella gallinarum modificadas avirulentas; composición farmacéutica que la usan; aditivo para piensos; procedimiento de tratamiento de la tifosis aviar infecciosa por salmonellla gallinarum. (divisional solicitud 3285-2013)

Info

Publication number
CL2017000232A1
CL2017000232A1 CL2017000232A CL2017000232A CL2017000232A1 CL 2017000232 A1 CL2017000232 A1 CL 2017000232A1 CL 2017000232 A CL2017000232 A CL 2017000232A CL 2017000232 A CL2017000232 A CL 2017000232A CL 2017000232 A1 CL2017000232 A1 CL 2017000232A1
Authority
CL
Chile
Prior art keywords
gallinarum
typhosis
salmonellla
procedure
treatment
Prior art date
Application number
CL2017000232A
Other languages
English (en)
Inventor
Hyang Choi
Soo An Shin
Si Yong Yang
Young Wook Cho
Original Assignee
Cj Cheiljedang Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cj Cheiljedang Corp filed Critical Cj Cheiljedang Corp
Publication of CL2017000232A1 publication Critical patent/CL2017000232A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10311—Siphoviridae
    • C12N2795/10351—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Fodder In General (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN SE REFIERE A CEPAS DE SALMONELLA GALLINARUM MODIFICADAS AVIRULENTAS PRODUCIDAS POR INACTIVACIÓN DE AGRUPACIONES DE GENES DE VIRULENCIA DE SALMONELLA GALLINARUM (SG), UN PATÓGENO PRINCIPAL DE LA SALMONELOSIS AVIAR, Y DIVERSOS USOS DE LAS MISMAS, ESPECIALMENTE EN LA PRODUCCIÓN DE BACTERIÓFAGOS LÍTICOS ESPECÍFICOS DE SALMONELLA, COMPOSICIONES FARMACÉUTICAS Y ADITIVOS PARA PIENSOS.</p>
CL2017000232A 2011-05-17 2017-01-27 Cepas de salmonella gallinarum modificadas avirulentas; composición farmacéutica que la usan; aditivo para piensos; procedimiento de tratamiento de la tifosis aviar infecciosa por salmonellla gallinarum. (divisional solicitud 3285-2013) CL2017000232A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161487137P 2011-05-17 2011-05-17
US13/274,854 US8481052B2 (en) 2011-05-17 2011-10-17 Avirulent Salmonella gallinarum variants and pharmaceutical composition using the same

Publications (1)

Publication Number Publication Date
CL2017000232A1 true CL2017000232A1 (es) 2017-07-28

Family

ID=47175080

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2013003285A CL2013003285A1 (es) 2011-05-17 2013-11-15 Cepas de salmonella gallinarum modificadas avirulentas; composicion farmaceutica que la usan; aditivo para piensos; procedimiento de tratamiento de la tifosis aviar infecciosa por salmonella gallinarum.
CL2017000232A CL2017000232A1 (es) 2011-05-17 2017-01-27 Cepas de salmonella gallinarum modificadas avirulentas; composición farmacéutica que la usan; aditivo para piensos; procedimiento de tratamiento de la tifosis aviar infecciosa por salmonellla gallinarum. (divisional solicitud 3285-2013)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2013003285A CL2013003285A1 (es) 2011-05-17 2013-11-15 Cepas de salmonella gallinarum modificadas avirulentas; composicion farmaceutica que la usan; aditivo para piensos; procedimiento de tratamiento de la tifosis aviar infecciosa por salmonella gallinarum.

Country Status (11)

Country Link
US (3) US8481052B2 (es)
EP (1) EP2710116B1 (es)
KR (1) KR101500805B1 (es)
CN (2) CN104053768B (es)
BR (1) BR112013029677A2 (es)
CL (2) CL2013003285A1 (es)
DO (1) DOP2013000270A (es)
ES (1) ES2724729T3 (es)
PE (1) PE20141452A1 (es)
PH (1) PH12013502363B1 (es)
WO (1) WO2012157989A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8481052B2 (en) 2011-05-17 2013-07-09 Cj Cheiljedang Corporation Avirulent Salmonella gallinarum variants and pharmaceutical composition using the same
KR101465605B1 (ko) * 2013-01-25 2014-11-27 강원대학교산학협력단 ssrAB, rpoS 및 hmp 유전자가 결손된 살모넬라 갈리나룸 균주 및 이를 유효성분으로 포함하는 가금 티프스 예방용 백신 조성물
WO2016077453A1 (en) * 2014-11-11 2016-05-19 Ohio State Innovation Foundation Probiotic bacteria for the prevention and treatment of salmonella
KR101774863B1 (ko) 2015-07-20 2017-09-05 강원대학교산학협력단 살모넬라증 치료를 위한 변이 균주 ｈｉｄ２０９２와 ｈｉｄ２１１４ 및 이를 포함하는 살모넬라증 약제학적 조성물
US10576114B2 (en) 2015-11-25 2020-03-03 Universidad De Los Andes Composition comprising bacteriophages for reducing, eliminating and/or preventing Salmonella enteritidis, Salmonella typhimurium and Salmonella paratyphi B
CN109486714B (zh) * 2018-12-07 2020-08-04 扬州大学 一种鸡伤寒沙门氏菌弱毒分离株及其应用
CA3133479A1 (en) * 2019-03-29 2020-10-08 Purina Animal Nutrition Llc Bacteriophage animal feed preservative
CN110846427A (zh) * 2019-12-24 2020-02-28 江苏意诺飞生物科技有限公司 人类肠道病原菌感染诊断用鼠伤寒沙门菌特异性基因探针
KR102327091B1 (ko) * 2020-06-18 2021-11-16 전남대학교 산학협력단 암의 치료용 살모넬라 균주 및 이의 용도
CN117480255A (zh) * 2021-04-30 2024-01-30 全南大学校产学协力团 减毒鸡沙门氏菌菌株及其用途
KR102767904B1 (ko) * 2021-05-26 2025-02-18 서울대학교산학협력단 살모넬라 갈리나룸 변이균주 및 이의 용도
WO2024137831A2 (en) * 2022-12-22 2024-06-27 Purdue Research Foundation Bacteriophages and use thereof for the treatment or prevention of infection caused by salmonella gallinarum

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69526377T2 (de) * 1994-12-09 2002-11-07 Microscience Ltd Virulenzgene in der VGC2-Region von Salmonella
WO2000014240A2 (en) * 1998-09-04 2000-03-16 Creatogen Aktiengesellschaft Attenuated salmonella sp12 mutants as antigen carriers
GB9910812D0 (en) 1999-05-10 1999-07-07 Microscience Ltd Vaccine composition
AU5695701A (en) 2000-03-17 2001-10-03 Upjohn Co Salmonella vaccine materials and methods
KR100436740B1 (ko) * 2003-09-20 2004-06-22 주식회사 인트론바이오테크놀로지 살모넬라 갈리나룸 약독주 및 이를 포함하는 가금티푸스예방용 백신 조성물
US20080124355A1 (en) * 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
CN101204584A (zh) * 2007-12-17 2008-06-25 北京娜可长今国际银离子科技开发有限公司 以减毒沙门氏菌为载体的肿瘤疫苗及其制备方法
KR101070938B1 (ko) * 2008-12-02 2011-10-06 씨제이제일제당 (주) 신규한 박테리오파지 및 이를 포함하는 항균 조성물
KR101151532B1 (ko) 2008-12-24 2012-05-30 씨제이제일제당 (주) 신규한 박테리오파지 및 이를 포함하는 항균 조성물
KR101151516B1 (ko) 2008-12-24 2012-05-30 씨제이제일제당 (주) 신규한 박테리오파지 및 이를 포함하는 항균 조성물
US8647640B2 (en) * 2009-06-24 2014-02-11 Richard E. COWART Vaccine compositions and methods of use to protect against infectious disease
US8481052B2 (en) 2011-05-17 2013-07-09 Cj Cheiljedang Corporation Avirulent Salmonella gallinarum variants and pharmaceutical composition using the same

Also Published As

Publication number Publication date
US8481052B2 (en) 2013-07-09
WO2012157989A2 (en) 2012-11-22
CN107083351A (zh) 2017-08-22
CN104053768A (zh) 2014-09-17
EP2710116A2 (en) 2014-03-26
CN104053768B (zh) 2020-10-30
US8524243B2 (en) 2013-09-03
WO2012157989A3 (en) 2013-01-24
US9192658B2 (en) 2015-11-24
PH12013502363A1 (en) 2014-01-27
BR112013029677A2 (pt) 2017-01-24
CN107083351B (zh) 2021-09-14
PE20141452A1 (es) 2014-10-23
CL2013003285A1 (es) 2014-06-13
ES2724729T3 (es) 2019-09-13
PH12013502363B1 (en) 2018-10-05
US20120294892A1 (en) 2012-11-22
KR20120128583A (ko) 2012-11-27
EP2710116A4 (en) 2014-12-24
US20130022574A1 (en) 2013-01-24
EP2710116B1 (en) 2019-03-27
DOP2013000270A (es) 2014-03-31
US20130202643A1 (en) 2013-08-08
KR101500805B1 (ko) 2015-03-09

Similar Documents

Publication Publication Date Title
CL2019002204A1 (es) Compuestos inhibidores del vih.
UY32174A (es) Nuevos heterociclos sustituidos, composiciones farmaceuticas conteniendolos, procedimientos de preparacion y aplicaciones
DOP2013000270A (es) Cepas de salmonella gallinarum modificadas avirulentas y composiciones farmacéuticas que las usan
AU2015296298A8 (en) Flagellin-based agents and uses including effective vaccination
BR112017010354A2 (pt) compostos de triazolopirimidina e usos dos mesmos
UY33370A (es) Composiciones farmacéuticas comprendiendo un fármaco inhibidor de la DPP4 y de la pioglitazona, procedimientos de preparación y utilización
UA117796C2 (uk) Похідні хіназоліну, що застосовуються для лікування віл
CY1118678T1 (el) Παραγωγα καρβοξαμιδιου χλωρο-πυραζινης χρησιμα για την θεραπευτικη αντιμετωπιση ασθενειων που ευνοουνται απο την ανεπαρκη ενυδατωση του βλεννογονου
BR112014021531A8 (pt) composto, composição farmacêutica e usos dos mesmos
ECSP13012958A (es) Inhibidores de benzodioxano de la producción de leucotrieno.
CY1118858T1 (el) Νεα παραγωγα πυριμιδινης, παρασκευη αυτων και φαρμακευτικη χρηση αυτων ως αναστολεων φωσφορυλιωσης ακτ(ρκβ)
CO7310531A2 (es) 4-metil-2,3,8,9,9b-pentaaza-ciclopenta [a] naftalenos
CY1116775T1 (el) Παραγωγα πυριμιδονης ως αναστολεις της ιστικης τρανσγλουταμινασης
NI201400022A (es) Composición farmacéutica que comprende un ciclopolisacárido
MX2014005342A (es) Inhibidores del virus de la hepatitis c.
CY1121063T1 (el) Αναστολεις της συνθασης της αλδοστερονης
ECSP16062173A (es) Derivados de ácido heteroaril butanóico como inhibidores de lta4h
PH12017500595A1 (en) Aldosterone synthase inhibitors
BR112017006552A2 (pt) composições e métodos para inibir a atividade biológica de biomoléculas solúveis
MX370270B (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
MX2017004312A (es) Composicion farmaceutica oral de baja dosis de isotretinoina.
BR112014009760A2 (pt) análogos de ácido siálico, seu uso e composição farmacêutica e composição farmacêutica de liberação sustentada os compreendendo
CO7121334A2 (es) Formulaciones vesiculares
CY1115983T1 (el) Συνθεση toy aliskiren
BR112016007031A8 (pt) composição farmacêutica oral sólida, processo para preparar a composição farmacêutica oral sólida, e uso de uma composição farcêutica oral sólida